Zeta MUM1 Antibody. Zeta’s rabbit recombinant antibody recognizes MUM1/IRF4 (Inteferon Regulatory Factor 4), a nuclear transcription factor necessary for developing and activating B lymphocytes. MUM1 belongs to the IRF gene family containing at least 10 widely expressed genes with similar DNA binding motifs, all involved in the regulation of cell growth, transformation and induction of apoptosis, and development of T-cell immune response. MUM1+ cells are mainly located in the light zone of the germinal center but the highly proliferating, follicle colonizing B blasts of the dark zone fail to express the MUM1 protein. MUM1 expression may denote the final step of intragerminal center B cell differentiation as well as subsequent steps of B cell maturation toward plasma cells. Loss of MUM1 function results in the absence of activated lymphoid cells and Ig secreting plasma cells.
MUM1 is found mainly in B-cell lymphoma and melanocytic lesions. There is significant variation in positivity, mainly due to chromosomal translocations involving the MUM1 gene among T-cell lymphomas. MUM1 is useful in a panel with other markers for subclassifying malignant lymphomas and identifying plasma cell differentiation. Particularly, MUM1 may be helpful in the identification of plasma cell differentiation when morphologic evidence is lacking, and Ig light chains are difficult to interpret.
MUM1 can be helpful in a variety of additional applications for pathologists including but not limited to:
MUM1 is one of the markers used in Hans algorithm (requires immunostains CD10, BCL6 and MUM1) for the subclassification of diffuse large B cell lymphoma (DLBCL) into germinal center B cell-like subtype and nongerminal center B cell-like subtype.
MUM1 may help differentiate classic Hodgkin lymphoma (MUM1+) from nodular lymphocyte predominant Hodgkin lymphoma (MUM1-).
MUM1 differentiates the double hit lymphomas (MUM1+) from Burkitt and diffuse large B cell lymphoma (MUM1-).
MUM1 differentiates angioimmunoblastic T cell lymphoma (AITL) with Hodgkin/Reed-Sternberg (HRS)-like cells from classic Hodgkin lymphoma.
MUM1 expression differentiates tumors in the PEComa family from clear cell sarcoma and melanoma.
MUM1 expression is associated with poor outcomes for diffuse large B cell lymphomas, myelomas, and peripheral T cell lymphomas.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.